WEBULL
WebtradeDownload

BioCryst Pharmaceuticals (BCRX) Puts Orladeyo Growth And Valuation Back In Focus

Simply Wall St · 2d ago

BioCryst Pharmaceuticals (BCRX) has drawn investor attention after recent trading left the stock at US$8.68, with returns mixed over the past month and past 3 months but positive year to date.

For context, BioCryst Pharmaceuticals has posted a 6.9% 7 day share price gain but is still down 9.1% over 30 days. Its 12.73% 1 year total shareholder return and 18.10% 3 year total shareholder return indicate a recovery that has not fully offset the 41.82% total shareholder return decline over five years. This suggests that momentum has picked up recently after a weaker multi year stretch, as investors reassess both growth potential and risk around its rare disease portfolio.

Scan beyond BioCryst Pharmaceuticals and compare its recent momentum with a hand picked group of 35 high quality undervalued stocks that also pair cash generation with balance sheet strength.

The recent jump in BioCryst Pharmaceuticals, alongside a share price that sits far below both analyst targets and estimated fair value, raises a blunt question: Is the market prudently discounting its rare disease risks or simply mispricing the story?

Most Popular Narrative: 59% Undervalued

At a last close of $8.68 versus a widely followed fair value estimate of $21.30, the valuation gap around BioCryst Pharmaceuticals hinges on whether its hereditary angioedema franchise and wider rare disease ambitions can translate into the earnings profile analysts have mapped out.

Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.

Anticipated approval and launch of new indications such as ORLADEYO granules for pediatric patients and expanded use in HAE with normal C1 inhibitor broadens the addressable market in an environment of growing global healthcare spending on rare disease therapies, which should further increase long-term revenues and earnings visibility.

See why 25 investors see BioCryst Pharmaceuticals as 59% undervalued.

Result: Fair Value of $21.30 (UNDERVALUED)

Still, BioCryst Pharmaceuticals leans heavily on ORLADEYO for revenue, and any setback in that product or early stage pipeline trials could quickly challenge this bullish narrative.

Find out about the key risks to this BioCryst Pharmaceuticals narrative.

Next Steps

Mixed sentiment around BioCryst Pharmaceuticals is clear, so consider acting promptly, review both the upside and the downside, and ground your own view in the 3 key rewards and 2 important warning signs.

Looking for more BioCryst Pharmaceuticals sized investment ideas?

If BioCryst Pharmaceuticals has sharpened your focus, do not stop here. Use well filtered stock ideas to widen your opportunity set and pressure test your thinking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.